Short answer
NEOGENOMICS INC (NEO) filed an 8-K current report with the SEC on July 28, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 fiscal 2026 results released July 28, 2026.
NEOGENOMICS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 fiscal 2026 results released July 28, 2026
- Detailed financial results and management commentary available in Exhibit 99.1
- Earnings disclosure furnished under Regulation FD, not filed under Exchange Act Section 18 liability
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $202M, up 11% YoY, with clinical revenue up 14% and NGS growth of 26%
- Adjusted EBITDA $14M, up 36%, while adjusted gross margin reached 48.1%, up from 45.4%
- GAAP net income $2M versus a $45M loss, helped by an $11M debt extinguishment gain
- FY2026 guidance raised: revenue $802M-$806M and adjusted EBITDA $56M-$58M
- $316M convertible offering at 0.75% due 2032 funded repurchase of approximately $276M of 2028 notes and $25M of stock repurchases
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other NEOGENOMICS INC 8-K filings
Get the next NEO 8-K as it lands
Follow NEO for push alerts, or ask the research agent what this filing means.